ClinicalTrialsFinder
RecruitingPhase 3NCT04217733

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

A Comparative Study to Assess Safety and Effectiveness of Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Sponsor

Tanta University

Enrollment

60 participants

Start Date

Nov 1, 2019

Study Type

INTERVENTIONAL

Conditions

IBS - Irritable Bowel Syndrome

Summary

Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome

Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age ≥ 18 years,
  • Man and Women, Negative pregnancy test and effective contraception,
  • IBS defined by the Rome criteria IV
  • During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.
  • IBS Treatment stable for 1 month

Exclusion Criteria9

  • Breastfeeding
  • Diabetic patients
  • Significant liver function abnormalities (transaminases> 3N, cholestasis) and moderate renal disease (MDRD <60 ml / min)
  • Addiction to alcohol and / or drugs,
  • Antiepileptic drugs taken (epilepsy or chronic pain)
  • Chronic pain of greater intensity than that related to IBS,
  • Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline.
  • History or current severe depression (hospitalization, long-term antidepressant treatment)
  • Psychotic disorders,

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGpentoxyifylline

Pentoxyifylline two times daily for 3 months

DRUGMebeverine

Mebeverine 3 times for 3 months

DRUGethosuximide

ethosuximide 3 times for 3 months

Locations(1)

Sherief Abd-Elsalam

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04217733

Related Trials

Sucrase-Isomaltase (SI) Genes and Meal Load

NCT073096011 location

Gut Microbiome in Patients With Post-infectious Irritable Bowel Syndrome

NCT075170291 location

Ebastine Versus Mebeverine in IBS Patients

NCT058156025 locations

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT070894201 location

Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator

NCT066844701 location